SkyePharma Plc has updated investors on the company’s financial outlook as preparations continue for a potential launch of its asthma product, Flutiform. Revenues in 2010 are expected to show a modest increase from a year earlier. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
